Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

The Council today gave its final green light to setting up the Reform and Growth Facility for the Republic of Moldova, a new ...

As we show on Slide 11, MRD-6160 achieved dose dependent VAV1 degradation ... Our team is on track to file IND in the first half of this year, and on Slide 21, we have outlined our proposed ...

VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment Sys ...

VBP301, a Phase 1/2, multicenter, open-label, first-in-human study of VCAR33, is a transplant donor-derived anti-CD33 CAR-T ...

The lawsuit was against Sylvania Place Apartments, LLC” and “MRD Apartments, LLC. It claims disability-based discrimination, which violates the Fair Housing Act. It alleges that the defendants ...

DelveInsight's "CABLIVI Market Size, Forecast, and Market Insight Report" highlights the details around CABLIVI, a von Willebrand factor (vWF)-directed antibody fragment. The report provides product ...

Pin your favorite folders in File Explorer so you can find them quickly. Just right-click the folder and select Pin to Quick access. Add photos from your phone, your PC, and cloud storage to File ...

Bitte entschuldigen Sie den Fehler. Sollte dieser Fehler erneut auftreten, kontaktieren Sie bitte unseren Kundeservice per E-Mail.

1Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. 2Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai ...